Tubulis develops antibody-drug conjugates (ADCs) for the targeted therapy of cancer diseases with the aim of opening up new avenues in the treatment of tumors and providing patients with safe and effective ADCs. The basis for this is a proprietary platform consisting of novel drug chemistry, conjugation technologies and innovative target biology. This platform has been shown to address the core challenges of ADCs, enabling more effective and less toxic therapies.
Recently, the company closed its Series B financing round of EUR 60 million. This will be used to further develop and clinically validate Tubulis’ proprietary pipeline for the treatment of liquid and solid tumors.